A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-01 and is reviewed periodically as new material appears.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
==== Unstructured ==== An unstructured repository may simply be a stack of tapes, DVD-Rs or external HDDs with minimal information about what was backed up and when. This method is the easiest to implement, but unlikely to achieve a high level of recoverability as it lacks automation.
=== Biosynthetic pathway === The metabolic pathway to produce ergothioneine starts with the methylation of histidine to produce histidine betaine (hercynine). The sulfur atom is then incorporated from cysteine. The biosynthetic genes of ergothioneine have been described in detail for Mycobacterium smegmatis, Neurospora crassa, Schizosaccharomyces pombe (with homologues in Aspergillus, a genus important in food fermentation), and Caldithrix abyssi. This pathway has recently also been discovered in plants. Different groups of organisms use different approaches to sulfur-addition. Aerobic bacteria and fungi use an O2-dependent reaction that is catalyzed by a mononuclear non-heme iron enzyme, with cysteine or γ-glutamylcysteine as the sulfur source. Green sulfur bacteria and some archaea use a rhodanese-like sulfur transferase to perform oxidative polar substitution. Caldithrix uses a metallopterin-dependent bifunctional enzyme that combines an N-terminal domain similar to a tungsten-dependent acetylene hydratase and a C-terminal cysteine desulfurase domain. Homologs of the Caldithrix system are found in anaerobic bacteria and some archaea.
=== Books === ——; Wilson, E. B. (1985) [Originally published in 1935]. Introduction to Quantum Mechanics with Applications to Chemistry. Reprinted by Dover Publications. ISBN 978-0-486-64871-2. —— (1939). The Nature of the Chemical Bond and the Structure of Molecules and Crystals. Cornell University Press. —— (1947). General Chemistry: An Introduction to Descriptive Chemistry and Modern Chemical Theory. Freeman. Greatly revised and expanded in 1947, 1953, and 1970. Reprinted by Dover Publications in 1988. —— (1950). College Chemistry: An Introductory Textbook of General Chemistry. Freeman. 2nd edition, 1955. 3rd edition, 1964. —— (1970) [Originally published in 1964]. The Architecture of Molecules. (Illustrated by Roger Hayward). San Francisco: W. H. Freeman and Company. ISBN 978-0-7167-0158-3. Manuscript notes and typescripts (clear images) —— (1958). No more war!. Dodd, Mead & Co. ISBN 978-1-124-11966-3 —— (1977). Vitamin C, the Common Cold and the Flu. Freeman. ISBN 978-0-7167-0360-0. —— (1987). How to Live Longer and Feel Better. Avon. ISBN 978-0-380-70289-3. Cameron, E.; —— (1993). Cancer and Vitamin C: A Discussion of the Nature, Causes, Prevention, and Treatment of Cancer With Special Reference to the Value of Vitamin C. Camino. ISBN 978-0-940159-21-1. —— (1998). Linus Pauling On Peace: A Scientist Speaks Out on Humanism and World Survival. Rising Star Press. ISBN 978-0-933670-03-7. Hoffer, Abram; —— (2004). Healing Cancer: Complementary Vitamin & Drug Treatments. Toronto: CCNM Press. ISBN 978-1-897025-11-6. Ikeda, Daisaku; —— (2008).
Sources: en.wikipedia.org
Fundamentals of Oncology (1997; co‑editors: Miklós Kásler, István Ember, László Kopper, László Thurzó) Dictionary of Epidemiology (2003; co‑editor: Piroska V. Hajdú) The Health Status of the Hungarian Population at the Turn of the Millennium (2003) Preventive Medicine and Public Health (2006, 2012; first and second editions) Public Health Genomics (2013; co‑editors: Judit Sándor, Angela Brand) Public Health in Budapest (2014; co‑editor: Tamás Szentes) Health Diplomacy (2014; co‑editors: Mihály Kökény, Ilona Kickbusch) Public Health Medicine (2015; co‑editors: István Kárpáti, György Paragh) Preventive Services in Primary Care (2017; co‑editor: Magor Papp) Preventive Medicine and Public Health (third edition, 2023; co‑editors: István Kiss, Edit Paulik, János Sándor, Zoltán Ungvári)
The center of the DNA junction constitutes a volume on the order of a yoctoliter, hence the name YoctoReactor. This volume contains a single molecule reaction yielding reaction concentrations in the high mM range. The effective concentration facilitated by the DNA greatly accelerates chemical reactions that otherwise would not take place at the actual concentration several orders of magnitude lower.
The flying primate hypothesis proposed that when adaptations to flight are removed, megabats are allied to primates and colugos by anatomical features not shared with microbats, and thus flight evolved twice in mammals. Genomic studies, however, have contradicted this hypothesis, strongly supporting the common ancestry of all bats and the single origin of mammal flight.
On June 11, 2013, just days after being robbed at gunpoint in San Francisco, rapper 2 Chainz was arrested at Los Angeles International Airport on charges of possessing promethazine and codeine syrup (the primary ingredient of lean) along with marijuana. Mac Miller, who died of a drug overdose not involving lean, spoke openly of his addiction to lean. On April 7, 2015, Swedish rapper Yung Lean, while living in Miami Beach, Florida, and recording his second studio album Warlord, was hospitalized at Mount Sinai Medical Center due to an overdose stemming from an addiction to Xanax, cocaine, and lean. On November 26, 2024, rapper Lil Shine was charged with attempting to acquire controlled substances, after he and two others were accused of hacking into the Drug Enforcement Administration’s physicians system to acquire large amount of promethazine and codeine (the main ingredients in lean) with the intent to sell them.
Sources: en.wikipedia.org
=== The nucleic acid template hypotheses === Alexander Dounce, of the University of Rochester Medical Center in New York, came close to the correct interpretation of protein synthesis from RNA. In 1952, he proposed the first notion, naming it the "nucleic acid template hypotheses," that proteins were made from RNA, rather than from DNA. However, since the exact chemical structure of DNA or RNA was not known at the time, he suggested erroneously that proteins and RNA have complimentary sequences, as he described in Enzymologia: "the specific arrangement of amino acid residues in a given peptide chain is derived from the specific arrangement of nucleotide residues in a corresponding specific nucleic acid molecule." It was met with criticism in Nature the next year, to which Dounce defended his hypothesis:In the hypothesis proposed by me, ribonucleic acid was deliberately chosen as the template, since it seems probable from a number of considerations and experimental investigations that protein syn- thesis may occur in cytoplasm as well as in nuclei. There can be no objection at the present time to assuming that the genes are templates, but it is not necessary to assume that the genes act directly as templates for protein synthesis.
=== Optical storage and optoelectronics === Varying compositions of GeSbTe ("GST alloys") and Ag- and In- doped Sb2Te ("AIST alloys"), being examples of phase-change materials, are widely used in rewritable optical discs and phase-change memory devices. By applying heat, they can be switched between amorphous (glassy) and crystalline states. The change in optical and electrical properties can be used for information storage purposes. Future applications for GeSbTe may include, "ultrafast, entirely solid-state displays with nanometre-scale pixels, semi-transparent 'smart' glasses, 'smart' contact lenses, and artificial retina devices."
=== Greater Western Sydney === On 17 May 2022, it was announced that Hird would be joining the coaching staff at Greater Western Sydney as part-time assistant coach for the rest of the 2022 season under GWS caretaker senior coach and his former teammate Mark McVeigh, who replaced Leon Cameron after he resigned as the club's senior coach midway through the season. On 2 February 2023, Hird departed the club.
ΔG0 – empirically derived offset that in part corresponds to the overall loss of translational and rotational entropy of the ligand upon binding. ΔGhb – contribution from hydrogen bonding ΔGionic – contribution from ionic interactions ΔGlip – contribution from lipophilic interactions where |Alipo| is surface area of lipophilic contact between the ligand and receptor ΔGrot – entropy penalty due to freezing a rotatable in the ligand bond upon binding A more general thermodynamic "master" equation is as follows:
== Mechanism in the trp operon == The proposed mechanism of how this mRNA secondary structure and the trp leader peptide could regulate transcription of the trp biosynthetic enzymes includes the following.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.